Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could revolutionize Alzheimer's diagnosis, reducing need for spinal taps and scans

NCT ID NCT07680335

Diagnosis Sponsor: Alzheimercentrum Amsterdam Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at whether measuring certain proteins in the blood (p-tau217 and neurofilament light) can help doctors diagnose Alzheimer's disease more quickly and confidently in people with memory problems. About 550 participants visiting a memory clinic will have their blood tested, and researchers will track how the results change the diagnosis and the doctor's certainty. The goal is to see if blood-based biomarkers can replace or reduce the need for more invasive or expensive tests like spinal taps or brain scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Plasma p-tau217 and neurofilament light chain blood test
What this could lead to
If successful, this could make Alzheimer's diagnosis faster, less invasive, and more accessible, helping patients get the right care sooner.
What could go wrong
The study is observational and does not test a treatment. Blood tests may not be accurate enough in all cases, and results may not change how doctors manage patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 550 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient presents in memory clinic with cognitive complaints. * The physician is concerned about underlying AD as etiology of the complaints. * Adequate fluency in Dutch to understand informed consent procedure. Exclusion Criteria: * Age under 55. * Previous biomarker-confirmed diagnosis of AD. * Alcohol or drug abuse to such an extent that treatment would be advisable. * Patient is incapacitated, and is not able to judge consequences of participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer blood biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer blood biomarkers Alzheimer's disease(AD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, North Holland, 1081HV, Netherlands

  • Dijklander Ziekenhuis

    RECRUITING

    Purmerend, Netherlands

  • Elisabeth-TweeSteden Ziekenhuis

    NOT_YET_RECRUITING

    Tilburg, Netherlands

  • Flevoziekenhuis

    RECRUITING

    Almere Stad, Netherlands

  • Frisius MC

    RECRUITING

    Leeuwarden, Netherlands

  • Jeroen Bosch Ziekenhuis

    RECRUITING

    's-Hertogenbosch, Netherlands

  • Spaarne Gasthuis

    RECRUITING

    Haarlem, Netherlands

  • Tergooi MC

    RECRUITING

    Hilversum, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.